The global computational biology market was valued at $5.5 billion in 2021 and is projected to reach $31.5 billion by 2031, expanding at a remarkable CAGR of 19.5% from 2022 to 2031. This rapid growth is fueled by the increasing adoption of AI-powered drug discovery, disease modeling, preclinical development, and human body simulation software across pharmaceutical and academic sectors. Computational biology is revolutionizing how researchers understand biological systems — dramatically reducing drug development timelines and costs while improving clinical trial success rates. Both in-house and contract service models are scaling rapidly to meet demand from commercial enterprises and academic research institutions globally:
Market Snapshot:
- Market Value (2021): $5.5 Billion
- Forecast (2031): $31.5 Billion
- CAGR: 19.5%
- Forecast Period: 2022–2031
- Market Driver: AI and machine learning integration in drug discovery and biological simulation
- Key Applications: Drug discovery & disease modeling, preclinical drug development, clinical trials, cellular simulation
- Service Models: In-house development and contract-based computational services
- End Users: Academic & research institutions and commercial pharmaceutical companies
- Key Trends: Rise of digital twins, precision medicine, and systems biology platforms
- Regional Highlights: North America leads in investment; Europe and Asia-Pacific growing fast in academic and biotech adoption
Access Sample Data & Findings:
https://www.alliedmarketresearch.com/request-sample/12286
Increase in demand of pharmacovigilance, surge in the adoption and development of advanced software for drug discovery, and rise in demand for tools of computational biology in various fields such as genomics, epi-genomics, proteomics, and meta-genomics are expected to drive the growth of the global computational biology market. On the other hand, high initial cost & maintenance costs of the instruments are expected to hinder the growth to some extent. However, growing popularity of disease modeling of various diseases such as cardiovascular, cancer, and other infectious diseases is expected to create ample opportunities for the industry.
Factors that drive growth of the computational biology market share include increase in R&D activities for drug discovery, demand for predictive models, usage in population-based sequencing projects such as human genome project, and government funding. For instance, in March 2019, Ambrx Inc., a clinical-stage biopharmaceutical company focused in the field of protein therapeutics, signed R&D collaboration with BeiGene, Ltd., a commercial stage pharmaceutical company involved in the development of immuno-oncology drugs.
Ambrx has proprietary Expanded Genetic Code platform designed to incorporate a non-natural amino acid into protein sequences of both E-coli and Chinese Hamster Ovary (CHO) cells. With this collaboration, both will leverage Ambrx’s drug discovery platforms with the latter’s knowledge expertise and resource pool for the development of clinically advanced biologics drugs.
Increase in number of key players to launch various computational biology products and rise in number approvals for computational biology products notably contributed toward the market growth. For instance, in May 2021, Certara, Inc., the world leader in bio-simulation, released new versions of its quantitative systems pharmacology (QSP) simulators for immunogenicity (IG) and immuno-oncology (IO) to aid in the development of biologics and cancer treatments.
Key Market Players –
- Certara,
- Rhenovia
- Pharma SAS,
- Genedata AG,
- Rhenovia Pharma SAS & Leadscope Inc.,
- Entelos,
- Chemical Computing Group Inc.,
- Insilico Biotechnology AG,
- Compugen Ltd.,
- Nimbus Discovery LLC,
- Simulation Plus Inc.,
- Accelrys
★ See What’s Inside This Report @
https://www.alliedmarketresearch.com/checkout-final/4ce7bed98a3b8e2ae622f76f00a2a726
Moreover, in March 2021, Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, published a review article titled “Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis,” which looks at the biology and therapeutic relevance of the DNAM-1 axis in cancer immunotherapy.
Region wise, the computational biology market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America was the largest shareholder in the computational biology market in 2021. Increase in demand of pharmacovigilance for the pre-clinical drug development and to conduct clinical trials, R&D investments, and supportive government initiatives are the major factors and computational biology market trends that drive growth of the market.
LAMEA is estimated to grow fastest during the forecast period. Rise in number of product approval, increase in number of clinical trials procedures, surge in demand for bioinformatics tools & services emphasis of prominent players in enhancing their presence and high demand for advanced computational biology software in the region.
About Us
Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides end-to-end solutions along with information, education, advocacy, and networking resources to SMEs and early-stage start-ups to bring excellence to their processes. In addition, we offer a nurturing environment required to develop and grow businesses, including business planning; virtual support; market intelligence; acquiring resources; and getting direct access to finance, suppliers, and other experts to boost the growth of businesses and entrepreneurs.
Our bundled and hassle-free business support systems are customized to meet the needs of SME consultants and industry leaders. Moreover, our large network of skilled consultants and experts help start-ups get the business on a roll.
Contact:
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
[email protected]
